InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,070.55
(
0.00%
)
US TECH 100
17,096.80
(
0.55%
)
Dow Jones
38,503.69
(
0.00%
)
Brent Oil
87.30
(
-0.31%
)
Bitcoin
66,001.45
(
-0.62%
)
Post# of 251584
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119467
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 165404

Tuesday, 09/19/2017 11:54:14 AM

Tuesday, September 19, 2017 11:54:14 AM

Post# of 251584
GSK/INVA—FDA approves Trelegy Ellipta—first triple-MoA product for COPD:

http://www.gsk.com/en-gb/media/press-releases/trelegy-ellipta-approved-as-the-first-once-daily-single-inhaler-triple-therapy-for-the-treatment-of-appropriate-patients-with-copd-in-the-us/

Trelegy Ellipta contains an ICS, a LAMA, and a LABA.

INVA is the former THRX (#msg-119698593).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up